Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity

preview_player
Показать описание
Speaker: Jamie Dean, University College London
Date: September 18, 2024

  1. Fields Institute
Рекомендации по теме
Results from a 0:08:23

Results from a phase I study of AMG 160

Phase I study 0:01:24

Phase I study of plamotamab in R/R NHL

Phase I study 0:01:40

Phase I study of the ATR inhibitor M1774 in patients with solid tumors

The first in-human 0:04:24

The first in-human Phase I study of a BET inhibitor for the treatment of NHL

Phase I study 0:01:01

Phase I study of ruxolitinib plus abemaciclib for patients with myelofibrosis

Phase I study 0:19:03

Phase I study of a novel glioblastoma radiation therapy schedule exploiting cell-state plasticity

Phase I study 0:05:00

Phase I study of ven/aza maintenance therapy following ven/FluBu2 RIC alloSCT in high-risk MDS/AML

Dr. Desai on 0:00:59

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

Emergence of hadrons 1:06:45

Emergence of hadrons in cold nuclear matter

Phase I study 0:01:46

Phase I study of costimulatory bispecific antibody RO7227166 combined with glofitamab in R/R B-NHL

Findings of a 0:04:58

Findings of a Phase I study of anitocabtagene autoleucel for the treatment of R/R myeloma

A Phase I 0:01:06

A Phase I study of FHD-286, a novel BRG1/BRM inhibitor, in metastatic uveal melanoma

Phase I study 0:00:51

Phase I study of copanlisib plus venetoclax in R/R DLBCL

Phase I study 0:01:43

Phase I study of anti-HER2 CAR-engineered monocytes in HER2-overexpressing solid tumors

First-in-human phase I 0:11:06

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dex in pts with RRMM

Clinical Trial: Phase 0:08:32

Clinical Trial: Phase I Study of NAM-NK Cells Immunotherapy, Veronika Bachanova, MD PhD

Updates on the 0:03:05

Updates on the Phase I study of FT-4202 for SCD

Results from a 0:02:53

Results from a Phase I study of rapcabtagene autoleucel (YTB323), a novel CAR-T therapy in DLBCL

Phase I study 0:02:50

Phase I study of ABBV383, a novel BCMAxCD3 bispecific antibody, in R/R multiple myeloma

Phase I study 0:02:10

Phase I study of ruxolitinib in combination with abemaciclib in patients with myelofibrosis

Phase I study 0:00:43

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

Phase I study 0:02:16

Phase I study of donor-derived γδ T cells as relapse prophylaxis post haplo/cy

Phase I study 0:04:23

Phase I study of olverembatinib in patients with R/R CML & Ph+ ALL

Phase I study 0:04:48

Phase I study results of M7824 for patients with HPV associated cancers